Pathology Laboratories, Inc. (PathLabs), in conjunction with our reference laboratory partners, is in the process of making updates to its test menu for various changes as fully described within the contents of this technical bulletin. Although some updates were effective in late April 2023, the majority are set for implementation on Monday, May 15, 2023, as disclosed in the chart provided herein.

Pathology Laboratories, Inc. (PathLabs) is in the process of making updates to our Test Directory based on changes being made by our reference laboratory partner, Clinical Pathology Laboratories (CPL), a Sonic Healthcare USA, Inc. affiliate of Austin, Texas.

Effective May 8, 2023, PathLabs is pleased to announce that CPL will change its analytic platform and method for Thyroglobulin Antibody (Anti-Tg) and Thyroid Peroxidase Antibody (Anti-TPO). The new methodology is electrochemiluminescence immunoassay (ECLIA).

As part of Pathology Laboratories, Inc.’s (PathLabs) continuous dedication to providing quality results and assure optimal cytology specimens, all Routine Non-Gynecologic fluids (e.g., urine for cytology and sputum) must be submitted in ThinPrep® CytoLyt® Solution. The ThinPrep® CytoLyt® Solution is a water-based, buffered cell wash solution designed to lyse red blood cells, prevent protein precipitation, dissolve mucus and preserve the morphology of the cellular material. When all Routine Non-Gynecologic fluids (e.g., urine for cytology and sputum) are placed in ThinPrep® CytoLyt® Solution, the specimen cellular material is properly preserved.

Pathology Laboratories, Inc. (PathLabs) is pleased to announce we will bring HPV, Pap, and STD (Sexually Transmitted Disease) Swab testing for Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), and Trichomonas vaginalis (TV) in-house, effective Thursday, March 2, 2023.

As a result of internalizing this testing, PathLabs is in the process of updating our HPV, Pap, and STD Swab tests; specifically, to accommodate an expanded test menu, introduce a new methodology for molecular testing, convey decreased analytic times, present a new collection device for the Roche platform, and initiate EMR code changes.

As of March 2nd, we are converting to a new Cytology/Histology Requisition (version 02/2023), shown at the end of this publication, to be used for ordering Cytology, Histology and Molecular testing. PathLabs’ sales team and supply department will be distributing the new requisition beginning next week.

All testing updates are disclosed in the context of this publication and provided in further detail in the charts below. All changes are marked in bright blue.

Pathology Laboratories, Inc. (PathLabs), a Sonic Healthcare Clinical Laboratory and division of Sonic Healthcare USA, Inc., is privileged to welcome Anastasia M. Canacci, M.D., as Medical Director. Dr. Canacci joins PathLabs with an extensive career in laboratory medicine.

Pathology Laboratories, Inc. (PathLabs) is in the process of making updates to the Reporting Titles and Result Code Descriptions of the STD (Sexually Transmitted Disease) Swab Testing for Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), and Trichomonas vaginalis (TV). The updates are based on changes being made by our reference laboratory partner, Clinical Pathology Laboratories (CPL), a Sonic Healthcare USA, Inc. affiliate in Austin, Texas. These updates will be effective at PathLabs beginning Monday, January 23, 2023, as disclosed in the chart provided herein.

Pathology Laboratories, Inc. (PathLabs) is in the process of making updates to certain CPT Codes for 2023, and various Order Code Reporting Titles and Result Codes Descriptions to better correlate with specific CPT Code Descriptions, as published by the American Medical Association. These changes will be effective Tuesday, January 3, 2023, as disclosed in the chart provided herein.

Pathology Laboratories, Inc. (PathLabs) is pleased to announce that we are bringing the STD (Sexually Transmitted Disease) testing for Chlamydia trachomatis (CT), Neisseria gonorrhea (NG), and Trichomonas vaginalis (TV) of urine specimens in-house effective December 27, 2022.